<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02012491</url>
  </required_header>
  <id_info>
    <org_study_id>818434</org_study_id>
    <secondary_id>1R01HD071920-01A1</secondary_id>
    <nct_id>NCT02012491</nct_id>
  </id_info>
  <brief_title>Comparative Effectiveness of Pregnancy Failure Management Regimens</brief_title>
  <acronym>PreFaiR</acronym>
  <official_title>Comparative Effectiveness of Pregnancy Failure Management Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the effectiveness of combination treatment
      (mifepristone premedication plus single-dose misoprostol) to single-dose misoprostol
      (standard of care) for the management of early pregnancy failure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">June 15, 2019</completion_date>
  <primary_completion_date type="Actual">May 15, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gestational Sac Expulsion With One Treatment Dose on Day 3 (Visit 2) and no Need for Additional Medical or Surgical Intervention Within 30 Days of Treatment.</measure>
    <time_frame>Day 3 (visit 2) and up to 30 days following visit (to ensure surgical measures were not done</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Gestational Sac Expulsion by the Second Follow-up Visit at Day 8</measure>
    <time_frame>Day 8 (visit 3) and up to 30 day to ensure additional measures were not done (surgical)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Gestational Sac Expulsion by the 30-day Telephone Call</measure>
    <time_frame>30 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Uterine Asperation</measure>
    <time_frame>30 Days</time_frame>
    <description>Surgical removal of the miscarriage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of Serious Adverse Events Between Study Arms.</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event Reported by Participants</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Spontaneous Abortion</condition>
  <arm_group>
    <arm_group_label>misoprostol plus mifepristone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>800 micrograms vaginal misoprostol, preceded by 200 milligrams oral mifepristone 24 hours prior</description>
  </arm_group>
  <arm_group>
    <arm_group_label>misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>800 micrograms of vaginal misoprostol alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <arm_group_label>misoprostol</arm_group_label>
    <arm_group_label>misoprostol plus mifepristone</arm_group_label>
    <other_name>Cytotec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone</intervention_name>
    <arm_group_label>misoprostol plus mifepristone</arm_group_label>
    <other_name>Mifeprex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  between 5 and 12 completed weeks gestation

          -  18 years or older

          -  hemodynamically stable

          -  confirmed diagnosis of intrauterine embryonic/fetal demise or anembryonic gestation
             (ultrasound examination demonstrates a fetal pole without cardiac activity measuring
             between 5.3 and 40 mm or an abnormal growth pattern diagnostic of early pregnancy
             failure)

          -  willing and able to give informed consent

        Exclusion Criteria:

          -  diagnosis of incomplete or inevitable abortion (absent gestational sac and/or active
             bleeding, open cervical os)

          -  contraindication to mifepristone (chronic corticosteroid administration, adrenal
             disease)

          -  contraindication to misoprostol (glaucoma, mitral stenosis, sickle cell anemia, or
             known allergy to prostaglandin)

          -  cardiovascular disease (angina, valvular disease, arrhythmia, or cardiac failure)

          -  most recent hemoglobin &lt;9.5 g/dL

          -  diagnosis of porphyria

          -  known clotting defect or receiving anticoagulants

          -  pregnancy with an intrauterine device (IUD) in place

          -  breastfeeding during the first 7 days of study participation

          -  unwilling to comply with the study protocol and visit schedule

          -  any evidence of viable pregnancy

          -  possibility of ectopic pregnancy

          -  known or suspected pelvic infection

          -  concurrent participation in any other interventional trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Courtney A Schreiber, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mitchell Creinin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>December 10, 2013</study_first_submitted>
  <study_first_submitted_qc>December 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2013</study_first_posted>
  <results_first_submitted>August 28, 2018</results_first_submitted>
  <results_first_submitted_qc>November 28, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 21, 2018</results_first_posted>
  <last_update_submitted>July 3, 2019</last_update_submitted>
  <last_update_submitted_qc>July 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spontaneous abortion</keyword>
  <keyword>Early Pregnancy Failure</keyword>
  <keyword>Mifepristone</keyword>
  <keyword>Misoprostol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Spontaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 7, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT02012491/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>We randomly assigned 300 women who had an anembryonic gestation or in whom embryonic or fetal death was confirmed to receive pretreatment with 200 mg of mifepristone, orally, followed by 800 μg of misoprostol, administered vaginally (mifepristone-pretreatment group), or 800 μg of misoprostol alone, administered vaginally (misoprostol-alone group).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Misoprostol</title>
          <description>800 micrograms of vaginal misoprostol alone
Misoprostol</description>
        </group>
        <group group_id="P2">
          <title>Misoprostol Plus Mifepristone</title>
          <description>800 micrograms vaginal misoprostol, preceded by 200 milligrams oral mifepristone 24 hours prior
Misoprostol
Mifepristone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
                <participants group_id="P2" count="149"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
                <participants group_id="P2" count="148"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Misoprostol</title>
          <description>800 micrograms of vaginal misoprostol alone
Misoprostol</description>
        </group>
        <group group_id="B2">
          <title>Misoprostol Plus Mifepristone</title>
          <description>800 micrograms vaginal misoprostol, preceded by 200 milligrams oral mifepristone 24 hours prior
Misoprostol
Mifepristone</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="151"/>
            <count group_id="B2" value="149"/>
            <count group_id="B3" value="300"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Participant's age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.2" lower_limit="18" upper_limit="46"/>
                    <measurement group_id="B2" value="30.7" lower_limit="18" upper_limit="46"/>
                    <measurement group_id="B3" value="30.4" lower_limit="18" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Only females where included in this study.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="300"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="132"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnosis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Anembryonic gestation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Embryonic of fetal death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Gestational Sac Expulsion With One Treatment Dose on Day 3 (Visit 2) and no Need for Additional Medical or Surgical Intervention Within 30 Days of Treatment.</title>
        <time_frame>Day 3 (visit 2) and up to 30 days following visit (to ensure surgical measures were not done</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Misoprostol</title>
            <description>800 micrograms of vaginal misoprostol alone
Misoprostol</description>
          </group>
          <group group_id="O2">
            <title>Misoprostol Plus Mifepristone</title>
            <description>800 micrograms vaginal misoprostol, preceded by 200 milligrams oral mifepristone 24 hours prior
Misoprostol
Mifepristone</description>
          </group>
        </group_list>
        <measure>
          <title>Gestational Sac Expulsion With One Treatment Dose on Day 3 (Visit 2) and no Need for Additional Medical or Surgical Intervention Within 30 Days of Treatment.</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Gestational Sac Expulsion by the Second Follow-up Visit at Day 8</title>
        <time_frame>Day 8 (visit 3) and up to 30 day to ensure additional measures were not done (surgical)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Misoprostol</title>
            <description>800 micrograms of vaginal misoprostol alone
Misoprostol</description>
          </group>
          <group group_id="O2">
            <title>Misoprostol Plus Mifepristone</title>
            <description>800 micrograms vaginal misoprostol, preceded by 200 milligrams oral mifepristone 24 hours prior
Misoprostol
Mifepristone</description>
          </group>
        </group_list>
        <measure>
          <title>Gestational Sac Expulsion by the Second Follow-up Visit at Day 8</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Gestational Sac Expulsion by the 30-day Telephone Call</title>
        <time_frame>30 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Misoprostol</title>
            <description>800 micrograms of vaginal misoprostol alone
Misoprostol</description>
          </group>
          <group group_id="O2">
            <title>Misoprostol Plus Mifepristone</title>
            <description>800 micrograms vaginal misoprostol, preceded by 200 milligrams oral mifepristone 24 hours prior
Misoprostol
Mifepristone</description>
          </group>
        </group_list>
        <measure>
          <title>Gestational Sac Expulsion by the 30-day Telephone Call</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Uterine Asperation</title>
        <description>Surgical removal of the miscarriage.</description>
        <time_frame>30 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Misoprostol</title>
            <description>800 micrograms of vaginal misoprostol alone
Misoprostol</description>
          </group>
          <group group_id="O2">
            <title>Misoprostol Plus Mifepristone</title>
            <description>800 micrograms vaginal misoprostol, preceded by 200 milligrams oral mifepristone 24 hours prior
Misoprostol
Mifepristone</description>
          </group>
        </group_list>
        <measure>
          <title>Uterine Asperation</title>
          <description>Surgical removal of the miscarriage.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Serious Adverse Events Between Study Arms.</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Misoprostol</title>
            <description>800 micrograms of vaginal misoprostol alone
Misoprostol</description>
          </group>
          <group group_id="O2">
            <title>Misoprostol Plus Mifepristone</title>
            <description>800 micrograms vaginal misoprostol, preceded by 200 milligrams oral mifepristone 24 hours prior
Misoprostol
Mifepristone</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Serious Adverse Events Between Study Arms.</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Event Reported by Participants</title>
        <time_frame>30 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Misoprostol</title>
            <description>800 micrograms of vaginal misoprostol alone
Misoprostol</description>
          </group>
          <group group_id="O2">
            <title>Misoprostol Plus Mifepristone</title>
            <description>800 micrograms vaginal misoprostol, preceded by 200 milligrams oral mifepristone 24 hours prior
Misoprostol
Mifepristone</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Event Reported by Participants</title>
          <units>adverse events</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="0" upper_limit="843"/>
                    <measurement group_id="O2" value="6.1" lower_limit="0" upper_limit="904"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected over a 30 day time frame</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Misoprostol</title>
          <description>800 micrograms of vaginal misoprostol alone
Misoprostol</description>
        </group>
        <group group_id="E2">
          <title>Misoprostol Plus Mifepristone</title>
          <description>800 micrograms vaginal misoprostol, preceded by 200 milligrams oral mifepristone 24 hours prior
Misoprostol
Mifepristone</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding resulting in blood transfusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Courtney Schreiber</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-615-5234</phone>
      <email>Courtney.Schreiber@uphs.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

